![](https://www.nextias.com/ca/wp-content/uploads/2023/07/3397448Screenshot_6.png)
In Context
- A draft foresight paper on synthetic biology released by the Department of Biotechnology.
Major Points
- The document looks at the global policies and protocols that have to be kept in mind while developing such a policy.
- It also attempts to define synthetic biology and how intellectual property rights will be applicable to resulting processes and products.
- It will later help in creating a national policy.
What is Synthetic Biology?
- Synthetic biology refers to the science of using genetic sequencing, editing, and modification to create unnatural organisms or organic molecules that can function in living systems.
- Synthetic biology enables scientists to design and synthesise new sequences of DNA from scratch.
- First usage:
- The term ‘synthetic biology’ was first used by Barbara Hobomin in 1980, to describe bacteria that had been genetically engineered using recombinant DNA technology.
- Synthetic biology was initially synonymous with ‘bioengineering’.
- In 2000, the term ‘synthetic biology’ was again introduced by Eric Kool and other speakers at the annual meeting of the American Chemical Society in San Francisco.
Applications
- Synthetic biology has applications in various fields from developing synthetic organisms for vaccination to creating natural products in a lab such as vanillin, the organic compound extracted from vanilla seeds, which can now be grown in yeasts with additional plant genomes.
- In the pharmaceutical industry, synthetic biology can be used to make natural compounds such as artemisinin used for the treatment of malaria and Car T cell therapy for cancer treatment.
- It is starting to be used in the fashion industry as well; some companies are exploring the possibility of dyeing jeans without producing hazardous waste.
- Then there are companies using it to deliver fixed nitrogen to plants instead of using fertilisers, engineering microbes to create food additives or brewing proteins.
- Other applications to therapeutics include engineered networks and organisms for disease-mechanism elucidation, drug-target identification, drug-discovery platforms, therapeutic treatment, therapeutic delivery, and drug production and access.
Risk and Challenges
- The great challenge of synthetic biology is that the biological systems are complex, and the operating principles are still not fully elucidated.
- The intentional or accidental release of genetically engineered organisms into the environment could have significant negative impacts on both human and environmental health.
- Misuse of these technologies and a failure to account for unintended consequences could cause irreversible environmental damage.
- Regulating the use of easily accessible and low-cost technologies like CRISPR will likely be a challenge for authorities.
- There is also growing concern that the technology could be misused by extremist groups.
- A unique ethical concern about synthetic biology is that it may result in the creation of entities that fall somewhere between living things and machines.
- It is not difficult to see why some products of synthetic biology might fail to fit comfortably into our intuitive dichotomy between the living and the non-living.
Way Forward
- Under the precautionary principle, stringent risk assessment and the inclusion of diverse stakeholder perspectives should be applied in the development and handling of innovative synthetic biology applications and products.
- It is time for India to consolidate its stand on the science of synthetic biology and communicate its interests and aspirations in relevant international fora with clarity and should avoid conflicting stands on science on one hand and policy on the other.
- It is time to create a policy for synthetic biology now more than ever as it is rapidly evolving with new discoveries happening every year.
- Soon we will start to see some products and we need to be ready with the regulatory framework.
- There is also a need to look at the benefits of the products and the risk it poses to biodiversity.
- Soon we will start to see some products and we need to be ready with the regulatory framework.
International treaties and organisations related to synthetic biology
|
Source: IE
Previous article
Stem Cell Transplant: Miracle Cure Against HIV
Next article
First information report (FIR)